Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $910,320 | 73 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AQUESTIVE THERAPEUTICS, INC. | $910,320 | 73 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $484,823 | 34 | AQUESTIVE THERAPEUTICS, INC. ($484,823) |
| 2021 | $302,891 | 27 | AQUESTIVE THERAPEUTICS, INC. ($302,891) |
| 2020 | $122,606 | 12 | AQUESTIVE THERAPEUTICS, INC. ($122,606) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $19,175.00 | Research |
| 10/31/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $20,475.00 | Research |
| 10/17/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $18,688.00 | Research |
| 10/17/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $15,600.00 | Research |
| 10/17/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $405.42 | Research |
| 10/17/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $405.42 | Research |
| 10/04/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $14,788.00 | Research |
| 09/20/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $18,281.00 | Research |
| 09/20/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $18,281.00 | Research |
| 09/13/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $19,906.00 | Research |
| 08/15/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $20,150.00 | Research |
| 08/15/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $1,372.40 | Research |
| 07/27/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $17,631.00 | Research |
| 07/18/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $22,588.00 | Research |
| 07/18/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $16,088.00 | Research |
| 07/07/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $19,094.00 | Research |
| 07/07/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $16,575.00 | Research |
| 07/07/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $16,575.00 | Research |
| 07/07/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $791.54 | Research |
| 06/15/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $35.00 | Research |
| 05/24/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $17,225.00 | Research |
| 05/10/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $21,938.00 | Research |
| 05/10/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $20,638.00 | Research |
| 05/10/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $20,638.00 | Research |
| 05/10/2022 | AQUESTIVE THERAPEUTICS, INC. | — | — | Cash or cash equivalent | $16,169.00 | Research |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| UNDERSTANDING PATIENT PERCEPTIONS AND PREFERENCES FOR DIFFERENT ROUTES OF ADMINISTRATION FOR CLUSTER SEIZURE TREATMENT | AQUESTIVE THERAPEUTICS, INC. | $43,957 | 4 |
| AN OPEN-LABEL, SAFETY AND TOLERABILITY STUDY OF CHRONIC INTERMITTENT USE OF DIAZEPAM BUCCAL FILM DBF IN PEDIATRIC, ADOLESCENT AND ADULT SUBJECTS WITH EPILEPSY | AQUESTIVE THERAPEUTICS, INC. | $43,750 | 4 |
| A MULTICENTER, OPEN-LABEL, CROSSOVER STUDY TO ASSESS THE PHARMACOKINETICS AND SAFETY OF DIAZEPAM BUCCAL FILM DBF IN PEDIATRIC SUBJECTS WITH EPILEPSY | AQUESTIVE THERAPEUTICS, INC. | $34,899 | 4 |
About Dr. Gary Slatko, MD
Dr. Gary Slatko, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2014. The National Provider Identifier (NPI) number assigned to this provider is 1659798189.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Slatko, MD has received a total of $910,320 in payments from pharmaceutical and medical device companies, with $484,823 received in 2022. These payments were reported across 73 transactions from 1 company. The most common payment nature is "" ($910,320).
Practice Information
- Specialty Internal Medicine
- Location New York, NY
- Active Since 03/21/2014
- Last Updated 03/21/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659798189
Products in Payments
- LIBERVANT (Drug) $122,606
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M